Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers

非人灵长类动物接种疫苗后对同源二级SHIV病毒攻击的保护作用取决于血清中和抗体滴度

阅读:2
作者:Matthias G Pauthner,Joseph P Nkolola,Colin Havenar-Daughton,Ben Murrell,Samantha M Reiss,Raiza Bastidas,Jérémie Prévost,Rebecca Nedellec,Benjamin von Bredow,Peter Abbink,Christopher A Cottrell,Daniel W Kulp,Talar Tokatlian,Bartek Nogal,Matteo Bianchi,Hui Li,Jeong Hyun Lee,Salvatore T Butera,David T Evans,Lars Hangartner,Andrés Finzi,Ian A Wilson,Richard T Wyatt,Darrell J Irvine,William R Schief,Andrew B Ward,Rogier W Sanders,Shane Crotty,George M Shaw,Dan H Barouch,Dennis R Burton

Abstract

Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge. However, conditions for nAb-mediated protection after vaccination have not been established. Here, we selected groups of 6 rhesus macaques with either high or low serum nAb titers from a total of 78 animals immunized with recombinant native-like (SOSIP) Env trimers. Repeat intrarectal challenge with homologous tier 2 SHIVBG505 led to rapid infection in unimmunized and low-titer animals. High-titer animals, however, demonstrated protection that was gradually lost as nAb titers waned over time. An autologous serum ID50 nAb titer of ∼1:500 afforded more than 90% protection from medium-dose SHIV infection. In contrast, antibody-dependent cellular cytotoxicity and T cell activity did not correlate with protection. Therefore, Env protein-based vaccination strategies can protect against hard-to-neutralize SHIV challenge in rhesus macaques by inducing tier 2 nAbs, provided appropriate neutralizing titers can be reached and maintained.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。